Outpatients | Inpatients | DEPRESSIVE DISORDER MAJOR WITHOUT PSYCHOTIC FEATURE
Item
outpatients or inpatients with nonpsychotic major depressive disorder (mdd).
boolean
C0029921 (UMLS CUI [1])
C0021562 (UMLS CUI [2])
C0743081 (UMLS CUI [3])
QIDS
Item
a score of >16 on the qids
boolean
C4300148 (UMLS CUI [1])
Antidepressant therapy Appropriate Outpatients | Antidepressant therapy Appropriate Inpatients
Item
outpatients or inpatients for whom antidepressant treatment is deemed appropriate by the treating clinician
boolean
C1096649 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C0029921 (UMLS CUI [1,3])
C1096649 (UMLS CUI [2,1])
C1548787 (UMLS CUI [2,2])
C0021562 (UMLS CUI [2,3])
Age
Item
subjects who are between 18-55 years of age
boolean
C0001779 (UMLS CUI [1])
Medical contraindication Citalopram
Item
contraindications to citalopram treatment
boolean
C1301624 (UMLS CUI [1,1])
C0008845 (UMLS CUI [1,2])
Axis I diagnosis | Axis II diagnosis | Exception Depressive disorder
Item
axis i or ii disorder other than depression that is the primary reason for seeking treatment intervention and/or psychiatric care
boolean
C0270287 (UMLS CUI [1])
C0270288 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0011581 (UMLS CUI [3,2])
Healthy Control | First Degree Relative Axis I diagnosis
Item
for healthy controls, a first degree relative who has been diagnosed with an axis i disorder
boolean
C2986479 (UMLS CUI [1])
C1517194 (UMLS CUI [2,1])
C0270287 (UMLS CUI [2,2])
Schizophrenia | Schizoaffective Disorder | Bipolar I disorder
Item
patients with schizophrenia, schizoaffective disorder, or bipolar i disorder
boolean
C0036341 (UMLS CUI [1])
C0036337 (UMLS CUI [2])
C0853193 (UMLS CUI [3])
Antidepressant therapy | Fluoxetine | Antidepressive Agents To be stopped | Status pre- Initiation Citalopram
Item
antidepressant treatment within 4 days of study (1 week if fluoxetine). subjects currently on antidepressant medication with subtherapeutic results in terms of depression management after providing informed consent, will undergo a medication taper and discontinuation prior to initiation of citalopram treatment. the subject must be off of previous antidepressants for at least 4 days week prior to starting citalopram (1 week if fluoxetine). the subject will be closely monitored by the research study psychiatrist (with or without additional monitoring from primary clinical psychiatric providers). the medication taper is left up to the research study psychiatrist in consultation with patient's primary care or psychiatric provider. study subjects who cannot be safely tapered from their medication or experience adverse effects during the taper will be excluded from the study
boolean
C1096649 (UMLS CUI [1])
C0016365 (UMLS CUI [2])
C0003289 (UMLS CUI [3,1])
C1272691 (UMLS CUI [3,2])
C0332152 (UMLS CUI [4,1])
C1704686 (UMLS CUI [4,2])
C0008845 (UMLS CUI [4,3])
Antidepressive Agents Management Nicotine Dependence | Antidepressive Agents Management Chronic pain | Antidepressive Agents Migraine prophylaxis
Item
study subjects using their antidepressant medication for management of nicotine dependence, chronic pain, migraine prophylaxis, or other diagnoses will not be eligible for the study
boolean
C0003289 (UMLS CUI [1,1])
C0376636 (UMLS CUI [1,2])
C0028043 (UMLS CUI [1,3])
C0003289 (UMLS CUI [2,1])
C0376636 (UMLS CUI [2,2])
C0150055 (UMLS CUI [2,3])
C0003289 (UMLS CUI [3,1])
C1142085 (UMLS CUI [3,2])
Antipsychotic Agents | Typical Antipsychotic | Atypical antipsychotic | Mood stabilizing drug | Lithium | Carbamazepine | Valproate | lamotrigine | gabapentin | Anticonvulsants | Allowed Trazodone Sleeplessness | Allowed Melatonin Sleeplessness | Allowed Diphenhydramine Sleeplessness | Allowed Benzodiazepines Anxiety | Allowed Lorazepam Anxiety
Item
subjects currently on antipsychotic medications (i.e., typical or atypical antipsychotic drugs) and mood stabilizing(e.g., lithium, carbamazepine, valproate, lamotrigine, gabapentin, or other anticonvulsants) are not eligible for the study. trazodone, melatonin, and diphenhydramine may be used as rescue medications for insomnia. benzodiazepines may be used for treatment of anxiety, not to exceed 4 mg/24 hour of lorazepam
boolean
C0040615 (UMLS CUI [1])
C2917392 (UMLS CUI [2])
C1276996 (UMLS CUI [3])
C1276998 (UMLS CUI [4])
C0023870 (UMLS CUI [5])
C0006949 (UMLS CUI [6])
C0080356 (UMLS CUI [7])
C0064636 (UMLS CUI [8])
C0060926 (UMLS CUI [9])
C0003286 (UMLS CUI [10])
C0683607 (UMLS CUI [11,1])
C0040805 (UMLS CUI [11,2])
C0917801 (UMLS CUI [11,3])
C0683607 (UMLS CUI [12,1])
C0025219 (UMLS CUI [12,2])
C0917801 (UMLS CUI [12,3])
C0683607 (UMLS CUI [13,1])
C0012522 (UMLS CUI [13,2])
C0917801 (UMLS CUI [13,3])
C0683607 (UMLS CUI [14,1])
C0005064 (UMLS CUI [14,2])
C0003467 (UMLS CUI [14,3])
C0683607 (UMLS CUI [15,1])
C0024002 (UMLS CUI [15,2])
C0003467 (UMLS CUI [15,3])
Antibiotics | ANTIBIOTICS FOR TOPICAL USE allowed
Item
subjects who are currently on an antibiotic or an antibiotic within 2 weeks. (topical antibiotics are ok)
boolean
C0003232 (UMLS CUI [1])
C3653723 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
Aspirin Daily | NSAIDs Daily | Warfarin Daily | Aspirin Low Dose allowed
Item
daily use of aspirin, nsaid's or warfarin (low dose of baby aspirin ok)
boolean
C0004057 (UMLS CUI [1,1])
C0332173 (UMLS CUI [1,2])
C0003211 (UMLS CUI [2,1])
C0332173 (UMLS CUI [2,2])
C0043031 (UMLS CUI [3,1])
C0332173 (UMLS CUI [3,2])
C2608320 (UMLS CUI [4,1])
C0683607 (UMLS CUI [4,2])
Informed Consent Unable
Item
subjects unable to give informed consent are excluded
boolean
C0021430 (UMLS CUI [1,1])
C1299582 (UMLS CUI [1,2])
Pregnancy
Item
pregnant subjects will be excluded
boolean
C0032961 (UMLS CUI [1])
Breast Feeding | Breast Feeding Continue Planned
Item
subjects who are currently breastfeeding and who plan to continue breastfeeding will be excluded
boolean
C0006147 (UMLS CUI [1])
C0006147 (UMLS CUI [2,1])
C0549178 (UMLS CUI [2,2])
C1301732 (UMLS CUI [2,3])
Postmenopausal state
Item
postmenopausal women are not eligible for this study
boolean
C0232970 (UMLS CUI [1])